Dr. Hazel Jones has been appointed as the Chief Executive Officer of Enhanc3D Genomics after successfully serving as interim CEO and COO. With over a decade of senior leadership experience in oncology research, Hazel brings expertise in drug development and operational change. Enhanc3D Genomics has developed GenLink3D, a genome-wide 3D-genome mapping technology that provides insights into gene regulation and diseases, enabling the discovery of novel targets and biomarkers. Hazel’s appointment as CEO is seen as crucial in driving the company’s global operations and strategic partnerships. The company’s goal is to identify the right target, in the right cell, for the right patient, optimizing the drug discovery process.
Source link
Enhanc3D Genomics appoints Hazel Jones as Chief Executive Officer
